sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Position in Avadel Pharmaceuticals
On January 23, 2026, The Vanguard Group, Inc. disclosed its position in Avadel Pharmaceuticals plc as per Form 8.3 under the Irish Takeover Panel Act. This disclosure is essential for entities holding 1% or more of relevant securities in the context of takeovers. Vanguard Group controls 5,861,243 ordinary shares, equating to 6.02% ownership of Avadel Pharmaceuticals.
Recent transactions involved the purchase of 546 shares and the sale of 284 shares, both at a unit price of $21.53 USD. Vanguard reported no dealings in cash or stock-settled derivatives related to Avadel's securities.
No other agreements or arrangements were disclosed by Vanguard Group about indemnities or options related to the relevant securities, and the company confirmed no existing deals to refrain from future transactions in Avadel shares.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.